Advanced Cancer Diagnostics Market Size, Share, Trends, & Industry Analysis Report By Test, By Indication, By End User, and By Region – Market Forecast, 2025–2034

The advanced cancer diagnostics market size is expected to reach USD 138.81 Billion by 2034, according to a new study by Polaris Market Research. The report “Advanced Cancer Diagnostics Market Share, Size, Trends, Industry Analysis Report: By Test, By Indication, By End User, and By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Advanced cancer diagnostics solutions provide early detection, accurate monitoring, and personalized testing for various cancer types. These solutions cover tumor marker tests, imaging-based diagnostics, molecular testing, genetic testing, and liquid biopsy, supporting hospitals, laboratories, and research institutes with efficient, minimally invasive, and scalable diagnostic services.

Market growth is driven by rising cancer prevalence, aging populations, and increasing healthcare expenditure. Moreover, AI integration, digitalization, and advanced diagnostic technologies are enhancing test accuracy, operational efficiency, and global competitiveness.

Advanced Cancer Diagnostics Market Report Highlights

Based on test, tumor marker tests dominated in 2024, driven by widespread adoption in early detection and routine monitoring.

In terms of indication, lung cancer diagnostics expected fastest growth due to rising incidence and awareness.

Based on end user, hospital associated labs dominated in 2024, supported by high patient throughput and advanced infrastructure.

North America dominated in 2024, backed by strong hospital infrastructure and high diagnostic adoption.

Asia Pacific projected fastest CAGR, fueled by expanding medical infrastructure and government screening programs.

Key players in the global market include Abbott Laboratories, Siemens Healthineers, Thermo Fisher Scientific Inc., Hologic, Inc., Qiagen, Bio-Rad Laboratories, Inc., Danaher Corporation, Sysmex Corporation, Becton Dickinson & Co., Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., and Myriad Genetics, Inc.

Polaris Market Research has segmented the market report based on test, indication, end user, and region:

By Test Outlook (Revenue, USD Billion, 2020–2034)

Tumor Marker Tests

Fine Needle Aspiration Cytology (FNAC) & Biopsy

Imaging-Based Diagnostics

Bone Marrow Aspiration & Biopsy

Immunohistochemistry (IHC) & Molecular Testing

Genetic Testing for Cancer

Liquid Biopsy

By Indication Outlook (Revenue, USD Billion, 2020–2034)

Breast Cancer

Lung Cancer

Colorectal Cancer

Melanoma

Blood Cancer

Prostate Cancer

Ovarian Cancer

Stomach Cancer

Liver Cancer

Other Indications

By End User Outlook (Revenue, USD Billion, 2020–2034)

Hospital Associated Labs

Independent Diagnostic Laboratories

Diagnostic Imaging Centers

Cancer Research Institutes

Other End Users

By Regional Outlook (Revenue, USD Billion, 2020–2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America Show more